大多数囊性纤维化患者的治疗方法
1Program of Molecular Medicine and the Program for Individualized Therapy at SickKids Hospital (CFIT), The Hospital for Sick Children, Toronto, ON, Canada; Departments of Physiology and Biochemistry, University of Toronto, Toronto, ON, Canada.
TRIKAFTA是一种FDA批准的新药,通过纠正F508del突变的缺陷来治疗囊性纤维化 (CF). 与之前的药物不同,它对具有这种突变的一个或两个副本的CF患者有效.
科学领域:
- 生物化学
- 遗传学
- 药理学
背景情况:
- 囊性纤维化 (CF) 是由CFTR基因突变引起的遗传性疾病.
- F508del突变是最常见的突变,导致蛋白质错误折叠和缺陷的离子传输.
- 之前的治疗针对的是同卵性F508del突变.
研究的目的:
- 评估TRIKAFTA在患有F508del突变的CF患者中的疗效.
- 为了比较TRIKAFTA在患有F508del突变的一个或两个副本的患者中的有效性.
主要方法:
- 涉及F508del突变的CF患者的临床试验.
- 根据已确定的CF结局措施评估药物疗效.
主要成果:
- TRIKAFTA是FDA批准的第三种治疗F508del相关缺陷的药物.
- 在患有至少一个F508del突变的CF患者中,TRIKAFTA显示出有效性.
- 在更广泛的患者适用性方面,TRIKAFTA表现优于前者.
结论:
- TRIKAFTA 在CF治疗方面取得了重大进展.
- 这种药物扩大了F508del突变的CF患者的治疗选择.
- 在异卵性F508del患者中TRIKAFTA的有效性扩大了其临床效用.
更多相关视频
08:00Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
相关概念视频
Cystic Fibrosis: Management
Sinus disease and chronic...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Chest Physiotherapy
Purpose
CPT is primarily used for patients with excessive bronchial secretions who have difficulty clearing...
Drugs for Treatment of Constipation-Predominant IBS
Chronic Pancreatitis II: Collaborative Care
Assessment:
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
